Zimmer Biomet : Description Reconciliation of Cash Flow from Operating Activities to Free Cash Flow
February 04, 2020 at 06:59 am EST
Share
ZIMMER BIOMET HOLDINGS, INC.
Reconciliation of Cash Flow from Operating Activities to Free Cash Flow
For the Quarterly and Year-to-Date Periods in Calendar Year Ending December 31, 2019
(in millions, unaudited)
Three Months Ended
Three Months Ended
Three Months Ended
Three Months Ended
Year Ended
March 31, 2019
June 30, 2019
September 30, 2019
December 31, 2019
December 31, 2019
Net cash provided by operating activities
$
283.6
$
301.0
$
577.9
$
423.3
$
1,585.8
Additions to instruments
(63.7)
(81.1)
(94.7)
(76.4)
(315.9)
Additions to other property, plant and equipment
(37.8)
(58.9)
(58.6)
(51.8)
(207.1)
Free cash flow
$
182.1
$
161.0
$
424.6
$
295.1
$
1,062.8
ZIMMER BIOMET HOLDINGS, INC.
Reconciliation of Cash Flow from Operating Activities to Free Cash Flow
For the Quarterly and Year-to-Date Periods in Calendar Year Ending December 31, 2018
(in millions, unaudited)
Three Months Ended
Three Months Ended
Three Months Ended
Three Months Ended
Year Ended
March 31, 2018
June 30, 2018
September 30, 2018
December 31, 2018
December 31, 2018
Net cash provided by operating activities
$
490.5
$
393.3
$
484.1
$
379.5
$
1,747.4
Additions to instruments
(60.4)
(65.7)
(77.6)
(72.6)
(276.3)
Additions to other property, plant and equipment
(26.7)
(27.0)
(61.5)
(47.5)
(162.7)
Free cash flow
$
403.4
$
300.6
$
345.0
$
259.4
$
1,308.4
Attachments
Original document
Permalink
Disclaimer
Zimmer Biomet Holdings Inc. published this content on 04 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 February 2020 11:58:01 UTC
Zimmer Biomet Holdings, Inc. specializes in designing, manufacturing, and selling orthopedic and dental reconstruction implants, spinal implants, and traumatology products. Net sales break down by family of products as follows:
- reconstruction implants (57.5%): knees replacement (58.8% of net sales), hips replacement (41.2%);
- surgical products and traumatology equipment (22.1%);
- dental, spinal and craniomaxillofacial implants (12.8%);
- other (7.6%): primarily orthopedic surgery materials and instruments used during post-operative rehabilitation.
At the end of 2021, the group had approximately 30 production sites worldwide.
Net sales are distributed geographically as follows: Americas (61.3%), Europe/Middle East/Africa (21.3%) and Asia/Pacific (17.4%).
ZIMMER BIOMET HOLDINGS, INC. 
